Excellent report
28% improved pcp revenue growth
2.5% improved GM % on last half and 7% on pcp
If these trends continue we could be looking at NPAT in the vicinity of 1.2M for the FY, which in the context of operating leverage and 30% growth should command a multiple of 20x at least in this market or a market cap of 24M (0.68/share, a 15x multiple would be 0.51/share)
Excellent results.